



# HHS Public Access

Author manuscript

*Cell Dev Biol.* Author manuscript; available in PMC 2016 July 11.

Published in final edited form as:

*Cell Dev Biol.* 2015 December ; 4(3): . doi:10.4172/2168-9296.1000e138.

## Tumor Suppressors and Endodermal Differentiation of P19 Embryonic Stem Cells

Jyotshna Kanungo\*

Division of Neurotoxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA

### Keywords

Retinoic acid; P19 ES cell; Tumor suppressors; Endodermal differentiation

The P19 embryonic stem (ES) cells are derivatives of the inner cell mass of a mouse blastoderm, are multipotent and can give rise to all three germ layers [1]. They are anchorage-independent, display no contact inhibition, and are tumorigenic [2]. The P19 ES cell line was originally derived from a teratocarcinoma in C3H/HE mice, produced by grafting an embryo at 7 days of gestation to the testes of an adult male mouse [3, 4]. Depending on the nature of inducers, P19 ES cells can be driven to differentiate into derivatives of all three germ layers, an advantage that has been extensively exploited to study early developmental events. Dimethyl sulfoxide (DMSO) treatment of P19 ES cell aggregates (embryoid bodies) results in differentiation into cardiac- and skeletal muscle-like cells [1], whereas retinoic acid (RA) induces differentiation into neurons, glia, and fibroblast-like cells [5]. On the other hand, monolayers of P19 ES cells, when treated with RA, differentiate into cells with endodermal and mesodermal phenotypes [6]. The type of differentiation of P19 ES cell aggregates also depends on the RA concentration; with low concentration (10 nM) of RA, these cells differentiate into primitive endoderm-like cells and with high concentrations (1  $\mu$ M) of RA, differentiation is shifted towards neurons and glia [3, 7, 8].

Although extensive studies on RA-induced neuronal differentiation of P19 ES cells exist [9–12], very few studies report specific gene/protein-induced endodermal differentiation. For example, endodermal differentiation of P19 ES cells requiring G-proteins, such as  $G_{\alpha 13}$  and  $G_{\alpha 12}$  [13–15], JLP (JNK-interacting leucine zipper protein), a scaffold protein [16], a LIM-protein, Ajuba [17] and a tumor suppressor, Menin [18], has been shown.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

\*Corresponding author: Jyotshna Kanungo, PhD, Division of Neurotoxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, 3900 NCTR Road, Jefferson, AR 72079, USA, Tel: 870-543-7591; Fax: 870-543-7143; jyotshnabala.kanungo@fda.hhs.gov.

### Disclaimer

This document has been reviewed in accordance with United States Food and Drug Administration (FDA) policy and approved for publication. Approval does not signify that the contents necessarily reflect the position or opinions of the FDA, nor does mention of trade names or commercial products constitute endorsement or recommendation for use. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the FDA.

Tumor suppressors are characterized as proteins whose expression or activity needs to be attenuated for a cell to become cancerous [19]. In P19 ES cells, endodermal differentiation mediated by two tumor suppressors, Ku and Menin, has been reported [18, 20]. Ku is primarily involved in DNA repair and non-homologous recombination and is the heterodimeric regulatory component of the serine/threonine kinase, DNA-dependent protein kinase (DNA-PK) [21]. Ku consists of 80 (Ku80) and 70 kDa (Ku70) subunits [22]. Ku80 is also a somatostatin receptor that can regulate the activity of protein phosphatase 2A (PP2A) [23]. The fact that somatostatin is an inhibitor of cell proliferation and that PP2A is involved in cell cycle regulation [24] validated Ku80 as a suppressor of cell growth.

Ku reportedly inhibits rDNA transcription [25]. Retarded cell growth by Ku via repression of RNA polymerase I-mediated transcription has been demonstrated [26, 27]. Ku mediates the repression of mouse ribosomal gene transcription [28], and a member of the Ku protein family, non-histone protein 1 (NHP1) has been shown to be upregulated in differentiation of mouse myoblasts and human promyelocytes [29]. Furthermore, inhibition of the Ku heterodimer DNA binding activity, while the Ku protein level remained unaltered, was linked to granulocytic differentiation of human promyelocytic cell lines [30]. Report on the RNA polymerase I transcription-suppressive effects of Ku presented compelling evidence that Ku, directly or indirectly, could affect cell growth [31], and in turn may induce cell differentiation.

It has been reported that constitutively active  $G_{\alpha 12}$  and  $G_{\alpha 13}$  induced endodermal differentiation of P19 ES cells [13, 14] by modulating the MEKK4/JNK1 signaling pathway [15, 32]. Co-expression of an antisense Ku80 (AS-Ku80) reduced Ku80 expression in constitutively active  $G_{\alpha 13}$  ( $G_{\alpha 13}Q226L$ )-expressing cells and inhibited endodermal differentiation. The level of Ku70 also decreased in these cells indicating that the loss of one of the Ku subunits results in the loss of the other subunit [20]. This interdependence of the two Ku subunits for their stabilization has been reported [33, 34]. Overexpression of either  $G_{\alpha 13} Q226L$  or Ku80 down-regulated RNA polymerase I-mediated transcriptional activity whereas co-expression of AS-Ku80 restored the activity to control levels [20], but abrogated  $G_{\alpha 13}$ -mediated endodermal differentiation in P19 ES cells, indicating a critical role of Ku-80. However, Ku80 was not sufficient to induce endodermal differentiation in these cells [20] suggesting that Ku80 may be an indispensable protein downstream of  $G_{\alpha 13} Q226L$  signaling required for the endodermal differentiation of P19 ES cells [20].

Another tumor suppressor, Menin is a 61 kDa nuclear protein [35]. It is the product of the multiple endocrine neoplasia type I (*Men1*) gene, mutations of which, are known to cause the human autosomal dominant syndrome with development of tumors of the parathyroid, endocrine pancreas, and anterior pituitary [36]. A ubiquitously expressed protein, Menin bears no homology to functionally identified domains, but binds to JunD thus attenuating cell growth [37]. *Men1*-null mice are embryonically lethal suggesting the cause to be early developmental defects [38]. *Men1*-null embryonic fibroblasts enter senescence earlier than their wild-type counterparts and *Men1*-null ES cells can not form embryoid bodies suggesting an impaired differentiation capacity of these cells [38]. Menin's role in duct cell differentiation in mouse submandibular gland [39], and in early differentiation of osteoblasts but inhibition of their later differentiation, has been reported [40, 41]. Menin influences

*Hoxa9* gene expression and thereby regulates hematopoiesis and myeloid transformation [42, 43].

In P19 ES cells, RA modulated Menin expression, reduced cell growth and induced endodermal differentiation [18]. Although *Men1* over-expression suppressed P19 ES cell growth, the cells did not undergo endodermal differentiation in monolayer cultures, but did so upon cell aggregation. When aggregated in the presence of RA, these cells formed smaller embryoid bodies compared to the untreated ones and eventually underwent apoptosis [18]. Since endodermal differentiation occurred without RA in the P19 ES cell aggregates, the requirement of cell aggregation for Menin to induce endodermal differentiation in the absence of RA was hypothesized [18].

RA first binds to its nuclear receptor RAR $\alpha$  (retinoic acid receptor alpha) and then triggers the transcription of other downstream RARs, especially the RA-receptor and tumor suppressor, RAR $\beta$ 2 [44]. In the absence of RAR $\alpha$ , RA cannot execute its growth inhibitory effect [45]. Whether RA-induction of Menin expression in P19 ES cell aggregates, but not in cell monolayers, depended on RAR $\alpha$ -mediated RAR $\beta$ 2 activation regulating *Men1* transcription is not clear. However, Menin upregulated the mRNA of the three RARs (*RAR $\alpha$* , *RAR $\beta$*  and *RAR $\gamma$* ) in the P19 ES cell aggregates (embryoid bodies), but not in monolayers [18]. These findings indicated that not only is *Men1* an RA-responsive gene, but it also, in turn, induces the expression of the RARs. Induction of the expression of the RARs by Menin may be linked to the endodermal differentiation of P19 ES cells [18]. It's known that RA's differentiation-inducing function is mediated by ligand-dependent activation of the specific RARs. Therefore, Menin could activate the RARs in an RA-independent manner and thus result in endodermal differentiation of the P19 ES cells. For example, over-expression of either *Ngn1* or *Sox6* or *Stra13* has been shown to be sufficient to induce neuronal differentiation of P19 ES cells in the absence of RA [46–48]. Also in the absence of DMSO, certain transcription factors that induce mesodermal differentiation upon their over-expression in P19 ES cells include MEF2C and Nkx2—5 [49], GATA-4 [50], MyoD [51] and  $\beta$ -catenin [52]. In the embryoid bodies, only 10–20% of *Men1* over-expressing P19 ES cells at the core region underwent endodermal differentiation [18] indicating that Menin could regulate cellular differentiation that's co-dependent on cell microenvironment, cell adhesion, and inter-cellular signaling, etc. Therefore, Menin's interaction with other unidentified players in these biological processes (aggregation followed by endodermal differentiation) seems obvious. While Menin was sufficient to induce endodermal differentiation in aggregated P19 ES cells, the differentiation was inhibited by the pan-RAR antagonist Ro41-5253. Whether Menin regulates the RARs' transcriptional activation potential remains to be examined and so is the mechanism of the regulation of other downstream targets that are critical for endodermal differentiation. In summary, the study presented evidence that Menin, a known tumor suppressor, is a key player in the RA signaling pathway and is critical for endodermal differentiation [18].

P19 ES cells continue to serve as an ideal model system to study how various gene products including tumor suppressors affect early embryonic development and identify the mechanism(s) that regulate it. Most importantly, when a gene deletion or over-expression causes embryonic lethality thus prohibiting further studies on early developmental events,

P19 ES cells can be successfully utilized instead to recapitulate the early embryonic developmental processes. In addition, understanding the mechanism by which the tumor suppressors are regulated by the morphogen, RA, or the way they themselves regulate RA function by modulating the RARs, may prove useful in developing retinoid-based therapies for various diseases, especially cancer.

## References

1. McBurney MW, Jones-Villeneuve EM, Edwards MK, Anderson PJ. Control of muscle and neuronal differentiation in a cultured embryonal carcinoma cell line. *Nature*. 1982; 299:165–167. [PubMed: 7110336]
2. Martin GR. Teratocarcinomas and mammalian embryogenesis. *Science*. 1980; 209:768–776. [PubMed: 6250214]
3. Bain G, Ray WJ, Yao M, Gottlieb DI. From embryonal carcinoma cells to neurons: the P19 pathway. *Bioessays*. 1994; 16:343–348. [PubMed: 8024542]
4. McBurney MW, Rogers BJ. Isolation of male embryonal carcinoma cells and their chromosome replication patterns. *Dev Biol*. 1982; 89:503–508. [PubMed: 7056443]
5. Jones-Villeneuve EM, McBurney MW, Rogers KA, Kalnins VI. Retinoic acid induces embryonal carcinoma cells to differentiate into neurons and glial cells. *J Cell Biol*. 1982; 94:253–262. [PubMed: 7107698]
6. Mummery CL, Feijen A, Moolenaar WH, Van den Brink CE, De Laat SW. Establishment of a differentiated mesodermal line from P19 EC cells expressing functional PDGF and EGF receptors. *Exp Cell Res*. 1986; 165:229–242. [PubMed: 3011479]
7. Edwards MK, McBurney MW. The concentration of retinoic acid determines the differentiated cell types formed by a teratocarcinoma cell line. *Dev Biol*. 1983; 98:187–191. [PubMed: 6345235]
8. Rudnicki MA, Reuhl KR, McBurney MW. Cell lines with developmental potential restricted to mesodermal lineages isolated from differentiating cultures of pluripotential P19 embryonal carcinoma cells. *Development*. 1989; 107:361–372. [PubMed: 2483683]
9. Huang HS, Redmond TM, Kubish GM, Gupta S, Thompson RC, et al. Transcriptional regulatory events initiated by *Ascl1* and *Neurog2* during neuronal differentiation of P19 embryonic carcinoma cells. *J Mol Neurosci*. 2015; 55:684–705. [PubMed: 25189318]
10. Shimba K, Sakai K, Takayama Y, Kotani K, Jimbo Y. Recording axonal conduction to evaluate the integration of pluripotent cell-derived neurons into a neuronal network. *Biomed Microdevices*. 2015; 17:94. [PubMed: 26303583]
11. Soprano DR, Teets BW, Soprano KJ. Role of retinoic acid in the differentiation of embryonal carcinoma and embryonic stem cells. *Vitam Horm*. 2007; 75:69–95. [PubMed: 17368312]
12. Ulrich H, Majumder P. Neurotransmitter receptor expression and activity during neuronal differentiation of embryonal carcinoma and stem cells: from basic research towards clinical applications. *Cell Prolif*. 2006; 39:281–300. [PubMed: 16872363]
13. Jho EH, Davis RJ, Malbon CC. c-Jun amino-terminal kinase is regulated by Galpha12/Galpha13 and obligate for differentiation of P19 embryonal carcinoma cells by retinoic acid. *J Biol Chem*. 1997; 272:24468–24474. [PubMed: 9305908]
14. Jho EH, Malbon CC. Galpha12 and Galpha13 mediate differentiation of P19 mouse embryonal carcinoma cells in response to retinoic acid. *J Biol Chem*. 1997; 272:24461–24467. [PubMed: 9305907]
15. Kanungo J, Potapova I, Malbon CC, Wang H. MEKK4 mediates differentiation in response to retinoic acid via activation of c-Jun N-terminal kinase in rat embryonal carcinoma P19 cells. *J Biol Chem*. 2000; 275:24032–24039. [PubMed: 10807916]
16. Kashef K, Xu H, Reddy EP, Dhanasekaran DN. Endodermal differentiation of murine embryonic carcinoma cells by retinoic acid requires JLP, a JNK-scaffolding protein. *J Cell Biochem*. 2006; 98:715–722. [PubMed: 16619266]

17. Kanungo J, Pratt SJ, Marie H, Longmore GD. Ajuba, a cytosolic LIM protein, shuttles into the nucleus and affects embryonal cell proliferation and fate decisions. *Mol Biol Cell*. 2000; 11:3299–3313. [PubMed: 11029037]
18. Kanungo J, Chandrasekharappa SC. Menin induces endodermal differentiation in aggregated P19 stem cells by modulating the retinoic acid receptors. *Mol Cell Biochem*. 2012; 359:95–104. [PubMed: 21833538]
19. Sun W, Yang J. Functional mechanisms for human tumor suppressors. *J Cancer*. 2010; 1:136–140. [PubMed: 20922055]
20. Kanungo J, Wang HY, Malbon CC. Ku80 is required but not sufficient for Galpha13-mediated endodermal differentiation in P19 embryonic carcinoma cells. *Biochem Biophys Res Commun*. 2004; 323:293–298. [PubMed: 15351736]
21. Dvir A, Peterson SR, Knuth MW, Lu H, Dynan WS. Ku autoantigen is the regulatory component of a template-associated protein kinase that phosphorylates RNA polymerase II. *Proc Natl Acad Sci U S A*. 1992; 89:11920–11924. [PubMed: 1465419]
22. Mimori T, Hardin JA, Steitz JA. Characterization of the DNA-binding protein antigen Ku recognized by autoantibodies from patients with rheumatic disorders. *J Biol Chem*. 1986; 261:2274–2278. [PubMed: 3511059]
23. Le Romancer M, Reyl-Desmars F, Cherifi Y, Pigeon C, Bottari S, et al. The 86-kDa subunit of autoantigen Ku is a somatostatin receptor regulating protein phosphatase-2A activity. *J Biol Chem*. 1994; 269:17464–17468. [PubMed: 8021251]
24. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signaling. *Biochem J*. 2001; 353:417–439. [PubMed: 11171037]
25. Schnapp A, Pfeleiderer C, Rosenbauer H, Grummt I. A growth-dependent transcription initiation factor (TIF-IA) interacting with RNA polymerase I regulates mouse ribosomal RNA synthesis. *EMBO J*. 1990; 9:2857–2863. [PubMed: 2390974]
26. Datta PK, Budhiraja S, Reichel RR, Jacob ST. Regulation of ribosomal RNA gene transcription during retinoic acid-induced differentiation of mouse teratocarcinoma cells. *Exp Cell Res*. 1997; 231:198–205. [PubMed: 9056427]
27. Michaelidis TM, Grummt I. Mechanism of inhibition of RNA polymerase I transcription by DNA-dependent protein kinase. *Biol Chem*. 2002; 383:1683–1690. [PubMed: 12530533]
28. Kuhn A, Stefanovsky V, Grummt I. The nucleolar transcription activator UBF relieves Ku antigen-mediated repression of mouse ribosomal gene transcription. *Nucleic Acids Res*. 1993; 21:2057–2063. [PubMed: 8502546]
29. Oderwald H, Hughes MJ, Jost JP. Non-histone protein 1 (NHP1) is a member of the Ku protein family which is upregulated in differentiating mouse myoblasts and human promyelocytes. *FEBS Lett*. 1996; 382:313–318. [PubMed: 8605992]
30. Muller C, Monferran S, Gamp AC, Calsou P, Salles B. Inhibition of Ku heterodimer DNA end binding activity during granulocytic differentiation of human promyelocytic cell lines. *Oncogene*. 2001; 20:4373–4382. [PubMed: 11466618]
31. Labhart P. DNA-dependent protein kinase specifically represses promoter-directed transcription initiation by RNA polymerase I. *Proc Natl Acad Sci U S A*. 1995; 92:2934–2938. [PubMed: 7708751]
32. Wang HY, Kanungo J, Malbon CC. Expression of Galpha 13 (Q226L) induces P19 stem cells to primitive endoderm via MEKK1, 2, or 4. *J Biol Chem*. 2002; 277:3530–3536. [PubMed: 11700306]
33. Kanungo J. Exogenously expressed human Ku70 stabilizes Ku80 in *Xenopus* oocytes and induces heterologous DNA-PK catalytic activity. *Mol Cell Biochem*. 2010; 338:291–298. [PubMed: 20047046]
34. Satoh M, Wang J, Reeves WH. Role of free p70 (Ku) subunit in posttranslational stabilization of newly synthesized p80 during DNA-dependent protein kinase assembly. *Eur J Cell Biol*. 1995; 66:127–135. [PubMed: 7774599]

35. Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. *Cell*. 1999; 96:143–152. [PubMed: 9989505]
36. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. *Science*. 1997; 276:404–407. [PubMed: 9103196]
37. Agarwal SK, Novotny EA, Crabtree JS, Weitzman JB, Yaniv M, et al. Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. *Proc Natl Acad Sci U S A*. 2003; 100:10770–10775. [PubMed: 12960363]
38. Bertolino P, Radovanovic I, Casse H, Aguzzi A, Wang ZQ, et al. Genetic ablation of the tumor suppressor menin causes lethality at mid-gestation with defects in multiple organs. *Mech Dev*. 2003; 120:549–560. [PubMed: 12782272]
39. Hipkaeo W, Sakulsak N, Wakayama T, Yamamoto M, Nakaya MA, et al. Coexpression of menin and JunD during the duct cell differentiation in mouse submandibular gland. *Tohoku J Exp Med*. 2008; 214:231–245. [PubMed: 18323693]
40. Sowa H, Kaji H, Canaff L, Hendy GN, Tsukamoto T, et al. Inactivation of menin, the product of the multiple endocrine neoplasia type 1 gene, inhibits the commitment of multipotential mesenchymal stem cells into the osteoblast lineage. *J Biol Chem*. 2003; 278:21058–21069. [PubMed: 12649288]
41. Sowa H, Kaji H, Hendy GN, Canaff L, Komori T, et al. Menin is required for bone morphogenetic protein 2- and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx2. *J Biol Chem*. 2004; 279:40267–40275. [PubMed: 15150273]
42. Chen YX, Yan J, Keeshan K, Tubbs AT, Wang H, et al. The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. *Proc Natl Acad Sci U S A*. 2006; 103:1018–1023. [PubMed: 16415155]
43. Novotny E, Compton S, Liu PP, Collins FS, Chandrasekharappa SC. In vitro hematopoietic differentiation of mouse embryonic stem cells requires the tumor suppressor menin and is mediated by Hoxa9. *Mech Dev*. 2009; 126:517–522. [PubMed: 19393316]
44. Bastien J, Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. *Gene*. 2004; 328:1–16. [PubMed: 15019979]
45. Somenzi G, Sala G, Rossetti S, Ren M, Ghidoni R, et al. Disruption of retinoic acid receptor alpha reveals the growth promoter face of retinoic acid. *PLoS ONE*. 2007; 2:e836. [PubMed: 17786207]
46. Boudjelal M, Taneja R, Matsubara S, Bouillet P, Dolle P, et al. Overexpression of Stra13, a novel retinoic acid-inducible gene of the basic helix-loop-helix family, inhibits mesodermal and promotes neuronal differentiation of P19 cells. *Genes Dev*. 1997; 11:2052–2065. [PubMed: 9284045]
47. Hamada-Kanazawa M, Ishikawa K, Nomoto K, Uozumi T, Kawai Y, et al. Sox6 overexpression causes cellular aggregation and the neuronal differentiation of P19 embryonic carcinoma cells in the absence of retinoic acid. *FEBS Lett*. 2004; 560:192–198. [PubMed: 14988021]
48. Kim S, Yoon YS, Kim JW, Jung M, Kim SU, et al. Neurogenin1 is sufficient to induce neuronal differentiation of embryonal carcinoma P19 cells in the absence of retinoic acid. *Cell Mol Neurobiol*. 2004; 24:343–356. [PubMed: 15206818]
49. Skerjanc IS, Petropoulos H, Ridgeway AG, Wilton S. Myocyte enhancer factor 2C and Nkx2-5 up-regulate each other's expression and initiate cardiomyogenesis in P19 cells. *J Biol Chem*. 1998; 273:34904–34910. [PubMed: 9857019]
50. Grepin C, Nemer G, Nemer M. Enhanced cardiogenesis in embryonic stem cells overexpressing the GATA-4 transcription factor. *Development*. 1997; 124:2387–2395. [PubMed: 9199365]
51. Skerjanc IS, Slack RS, McBurney MW. Cellular aggregation enhances MyoD-directed skeletal myogenesis in embryonal carcinoma cells. *Mol Cell Biol*. 1994; 14:8451–8459. [PubMed: 7969178]
52. Petropoulos H, Skerjanc IS. Beta-catenin is essential and sufficient for skeletal myogenesis in P19 cells. *J Biol Chem*. 2002; 277:15393–15399. [PubMed: 11856745]